William Blair Keeps Their Buy Rating on Cellectis SA (CLLS)

By Jason Carr

William Blair analyst Raju Prasad maintained a Buy rating on Cellectis SA (CLLSResearch Report) today. The company’s shares closed last Monday at $17.96.

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 23.7% and a 62.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

Cellectis SA has an analyst consensus of Strong Buy, with a price target consensus of $42.75.

See today’s analyst top recommended stocks >>

The company has a one-year high of $20.84 and a one-year low of $9.50. Currently, Cellectis SA has an average volume of 116K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants.